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Cancer is the major cause of death in most
populations, with unhealthy lifestyles, bad diets,
and pollution exposures as contributing factors that
increase the risk of the disease. 1) Chemotherapy
drugs are used to reduce and kill malignant cancer
cells in the body. 2) However, medication therapy
management is required since chemotherapy often
affects healthy tissues or organs, producing unde-
sired side effects. Recently, many strategies have
been exploited to diminish the severe side effects of
anticancer drugs. One of those strategies involves
using nanoparticles to minimize the direct exposure
of drugs to healthy tissues, and to achieve specific
drug delivery into tumor tissues. 3)
It is known that tumor neovasculatures show
abnormalities in their structures, which lack
pericyte coverage and disorganized endothelial cell
arrangement, producing hyperpermeability of the
blood vessels. Therefore, macromolecules, including
nanoparticles in the blood plasma, would be al-
lowed to extravasate into the tumor interstitium.
The impaired lymphatic vessel networks in the
tumor will further reduce drainage of tumor inter-
stitial fluid. These two characteristics of the tumor
microenvironment create an enhanced permeation
and retention (EPR) effect that enable nanoparticles
to highly accumulate in tumor tissue, 4) as shown in
Fig. 1. However, the EPR effect is often limited by
passing time of intact nanoparticles through tumor
vascularization. The longer the circulation time of
nanoparticles in the bloodstream, the higher the
possibility of those nanoparticles to pass the leaky
tumor vasculatures, extravasate to, and be retained
in the tumor interstitium, producing high tumor
drug accumulation. 5) Therefore, the stability of
nanoparticles is important to obtain a prolonged
circulation time of intact nanoparticles in the blood-
stream. However, it should properly release the
drug in the tumor interstitium, or inside the cyto-
plasm of the cancer cells.
Of the many types of nanoparticles used for
the delivery of anticancer drugs, liposomes are a
superior drug delivery vehicle with many advan-
tages. 6) Liposomes are lipid vesicles composed of a
bilayer phospholipid membrane containing an inner
aqueous phase. This provides complete protection
for the drugs trapped inside against diffusion and
premature release. Furthermore, it can be
functionalized with polyethylene glycol (PEG) to en-
sure longer circulation in the bloodstream. This
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Figure. 1 Schematic illustration of tumor delivery in
liposomes. The leaky tumor vasculatures permit the
extravasation of liposomes into the tumor interstitium.
Furthermore, the impaired network of lymphatic vessels
reduces liposomal clearance, resulting in local retention
of liposomes in tumor tissue. These two features enable
liposomes to be highly accumulated in tumor tissues de-
fined as an enhanced permeation and retention (EPR)
effect.
creation of an aqueous PEG layer protects
liposomes from protein opsonization, thus reducing
reticulo-endothelial system uptake and providing a
high amount of intact liposomes for further delivery
into tumor tissues. 7) Depending on the characteris-
tics of the drugs, high drug encapsulation in
liposomes was achieved by using remote drug load-
ing methods. 8)
Doxorubicin (DOX, Fig. 2A) is an amphipathic
anthracycline compound, with water-insoluble
aglycone and a water-soluble basic amino sugar
moiety 9) , which has been widely used for cancer
treatment. Using the ammonium or pH gradient,
DOX can be actively loaded into the interior phase
of liposomes, producing stable DOX aggregates. 8) In
the case of ammonium sulfate (AS) as the
intraliposomal buffer, e.g. Doxil®, the presence of
sulfate ions and the low pH of the buffer produces
a stable entrapment of DOX inside liposomes, im-
proving accumulation of DOX in tumor tissue
through the EPR effect. 10) However, it has been re-
ported that insufficient cellular DOX release re-
duces the biological activity of Doxil®. 11)
Poly-, L-glutamic acid (PGA, Fig. 2B) is an
anionic polymer that contains a large number of
carboxyl groups that provide binding sites for cati-
onic DOX. 12) It has been reported that anionic
carboxylates of poly--glutamic acid could effectively
interact with cationic amines of DOX, producing
random aggregates and sustained release of DOX
in a pH-dependent manner. This would result in a
higher drug release at an acidic pH, representing
the tumor microenvironment, compared to the sys-
temic blood circulation at pH 7.4. 13) Therefore, the
use of PGA as an intraliposomal trapping agent
may provide an alternative method to produce
stable DOX entrapment in liposomes for tumor de-
livery of DOX via the EPR effect.
However, it has been known that tumor
neovascularization, which is mainly stimulated by
vascular endothelial growth factor (VEGF), pro-
duces abnormal vessel structures and poor tumor
blood flow that limits the tumor penetration of
drugs. 14) Anti-VEGF therapy is shown to produce
normalization of tumor vasculatures, thus improv-
ing tumor blood flow, which is required for uniform
tumor drug distribution. 15) It has been reported
that intravenous injection of zoledronic acid (ZOL)
enhances the antitumor activity of Doxil® in Lewis
lung carcinoma (LLC) tumor-bearing mice. 16) ZOL
showed a therapeutic intervention for producing
normalization of tumor vasculatures through deple-
tion of tumor-associated macrophages (TAMs) that
have potential to release angiogenic growth factors,
such as VEGF.
Therefore, in this study, we investigated the
use of PGA to improve stability of liposomal DOX.
The molecular weight of PGA has been evaluated
for the preparation and stability of liposomal DOX.
In combination with ZOL injection, the antitumor
activity of liposomal DOX prepared with PGA was
further determined on LLC tumor-bearing mice.
II. Liposome preparation and loading DOX
into PGA-liposomes
Generally, intraliposomal drug stabilization can
be achieved through complex formation or physical
aggregate-like compounds inside liposomes. 17-19)How-
ever, most of them use an acidified liposomal inte-
rior that can cause instability by lipid degradation
during long-term storage. In this study, PGA in a
0.65 M triethylamine (TEA) aqueous solution with
a neutral pH of 6.5 was used as the intraliposomal
buffer to control DOX loading and its release from
liposomes.
Liposomes were composed of hydrogenated soya
phosphatidylcholine (HSPC), cholesterol, and
methoxy- (polyethylene-glycol)-distearoyl phosphatidyl-
ethanolamine (PEG, mean molecular weight: 2,000)
at a molar ratio of 57:38:5, respectively, and pre-
pared by the thin film method. 20) PGA was used in
the hydration medium at a concentration of 2
mg/mL in 0.65 M TEA solution. Three different av-
erage molecular weights of PGA (4,800, 9,800, and
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Figure. 2Chemical structures of DOX (A) and PGA (B).
20,500) were used to prepare liposomal
DOX:PGA4800-L, PGA9800-L, and PGA20500-L, re-
spectively. As the control groups, 0.25 M AS or
0.65 M TEA solution were used for producing AS-L
or TEA-L, respectively.
Loading conditions for DOX into PGA-liposomes
(PGA-Ls) were optimized to ensure efficient drug
loading by using a TEA gradient. Two types of
extraliposomal buffer were used to load DOX: sa-
line, with pH of 6.5, and phosphate buffered saline
(PBS) at pH 7.4. As shown in Fig. 3A, by incubat-
ing the liposome-DOX mixtures at 60℃ for 10 min,
the use of saline could not effectively load DOX
into TEA-L, while the use of PBS pH 7.4 resulted
in a higher entrapment efficiency (6％ versus 96％,
respectively). In addition, increasing the incubation
period reduced the entrapment efficiencies of DOX
in TEA-L and PGA9800-L (Fig. 3B). 21) The percent-
age of DOX entrapped in PGA9800-L decreased
from 100％ to 78％ by increasing the incubation du-
ration from 10 to 60 min. As well as PGA9800-L,
TEA-L also showed a similar trend with a reduc-
tion of entrapment efficiency from 96％ (10 min) to
approximately 65％ by 60 min incubation at 60℃.
Furthermore, the DOX amount added to PGA-Ls
was then optimized by using three different
DOX/HSPC ratios, 1:1, 1:2, and 1:5 (w/w), during
DOX loading. As shown in Fig. 3C, increasing the
relative DOX amount to HSPC lowered the entrap-
ment efficiency. The highest DOX loading in PGA-
Ls was produced by loading DOX at a DOX/HSPC
ratio of 1:5 (w/w), as well being achieved in AS-L
and TEA-L, which were prepared at the same
drug/lipid ratio. 21)
When saline was used as the extraliposomal
buffer, only a small amount of DOX could be
loaded in liposomes, while PBS pH 7.4 produced a
high entrapment efficiency of DOX. It has been
known that, during drug loading, the unionized
fraction of DOX molecules in the extraliposomal
phase will diffuse to the intraliposomal phase,
while TEA in the intraliposomal phase will perme-
ate towards the extraliposomal phase, leaving pro-
tons that lower the pH of the liposomal interior
(Fig. 4). 22) This low pH protonates the permeated
DOX molecules, making them impermeable cationic
molecules. These conditions create a pH and drug
concentration gradient for further diffusion of un-
ionized DOX to accumulate and be precipitated in
limited trapped volume of aqueous core within the
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Figure. 3 Optimization of preparation conditions for
loading DOX into liposomes. 21) The entrapment effi-
ciency of DOX in TEA-L prepared with different
extraliposomal buffers (A), which were saline solution
(pH 6.5) and phosphate buffered saline (PBS) pH 7.4.
DOX was then loaded into TEA-L and PGA9800-L using
PBS pH 7.4 as the extraliposomal buffer by incubating
the mixtures in a water bath at 60℃ for 10, 30, and 60
min (B). The different DOX/HSPC weight ratios of 1:1,
1:2, and 1:5 were used to load DOX into AS-L, TEA-L,
and PGA-Ls by incubating the liposome-DOX mixtures
in a water bath at 60℃ for 10 min with PBS pH 7.4 as
the extraliposomal buffer (C).
Figure. 4 Schematic mechanism of DOX loading into
PGA-Ls by using TEA gradient. When DOX is added to
the extraliposomal phase, the unionized molecules of
DOX will diffuse into intraliposomal phase through
phospholipid bilayer of liposomes. In contrast, the un-
ionized TEA molecules will permeate towards
extraliposomal phase in a manner that is kinetically
and stoichiometrically correlated to the DOX uptake,
creating a self-buffered system. In a lower pH condition
of intraliposomal phase than pKa of DOX, these perme-
ated DOX molecules will be ionized forming positively
charged molecules that further interact with anionic
PGA. Through ionic interaction, they will produce DOX-
PGA ionic complexes.
liposomal vesicles. 10, 23) The similar pH of saline to
the 0.65 M TEA solution might not produce a large
concentration gradient for DOX diffusion, resulting
in a lower entrapment efficiency than when using
PBS pH 7.4.
According to these results, the use of PBS pH
7.4 as the extraliposomal buffer phase of liposomal
DOX could give high DOX loading by incubating
the liposome-DOX mixture at 60℃ for 10 min with
a DOX/HSPC ratio of 1:5 (w/w). Therefore, these
conditions were used to prepare PGA-Ls using a
0.65 M TEA solution as the intraliposomal buffer
phase for further studies.
III. The effects of PGA addition on the in
vitro stability and cytotoxicity of DOX en-
trapped in liposomes
PGA had no effects on liposome properties. 21)
Compared to AS-L and TEA-L, the addition of PGA
at different molecular weights exhibited no signifi-
cant differences on particle size and ζ-potential, as
shown in Fig. 5A-B. All liposomes were produced
with similar particle size, approximately 115 nm,
with slightly negative charges of ζ-potential. Fur-
thermore, high entrapment efficiencies of DOX were
achieved (>95％) in all PGA-Ls, as well as being
obtained in TEA-L and AS-L (Fig. 5C).
On the other hand, the use of PGA affected the
stability of DOX entrapped in PGA-Ls. 21) By evalu-
ating DOX release from liposomes using the dialy-
sis method for 24 and 48 h incubation, the highest
DOX release was observed as approximately 11％
and 19％, respectively, in TEA-L, while AS-L
showed the lowest drug release, at approximately
5％ and 8％ for 24 and 48 h, respectively (Fig. 6).
The use of PGA as a drug-trapping agent in PGA-
Ls lowered DOX release from liposomal DOX.
Among PGA-Ls, PGA20500-L showed significant de-
creases in DOX release, at 7％ (24 h) and 12％ (48
h).
Furthermore, the cytotoxicities of liposomal
DOX were evaluated for murine LLC cells by incu-
bating the cells with media containing DOX for 48
h. In correlation with the drug release study,
cytotoxicity of liposomal DOX was also highly af-
fected by the addition of PGA into liposomes. 21)
TEA-L showed approximately 4-fold lower
cytotoxicity than the DOX solution. The addition of
PGA into PGA-Ls reduced cytotoxicity of liposomal
DOX, which showed an approximately 3-fold higher
IC50 value than that of TEA-L, as shown in Fig. 7.
However, the cytotoxicities of PGA-Ls were similar
to each other. The IC50 values of PGA4800-L,
PGA9800-L, and PGA20500-L were 0.80, 0.92, and
0.95g/mL, respectively. Among the liposomal
DOX, AS-L showed the lowest cytotoxicity, which
produced approximately 38-fold reduced cytotoxicity
compared with the DOX solution.
In order to evaluate how PGA interacts with
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Figure. 5Characterization of liposomal DOX including
particle size (A), ζ-potential (B), and entrapment effi-
ciency of DOX (C). 21) Liposomes were prepared using
PBS pH 7.4 as the extraliposomal buffer. DOX was
added into liposomes at a DOX/HSPC weight ratio of
1:5, and then incubated in a water bath at 60℃ for 10
min. Each value represents the mean ± S.D. (n=3)
Figure. 6 Cumulative amount of DOX released from
liposomes taken at 24 and 48 h during the experiment. 21)
Liposomal DOX was added into a Spectra Por® 7 dialy-
sis membrane with molecular weight cut-off (MWCO) of
3,500 in phosphate-buffered saline (PBS) pH 7.4 with
continuous stirring in a water bath at 37℃. Each value
represents the mean ± S.D. (n=3). Data were analyzed
via one-way ANOVA followed by Tukey’s HSD post-hoc
test. * P < 0.05 versus TEA-L
DOX inside liposomes, the mixtures of PGA and
DOX solution were visually observed using an opti-
cal microscope. The effect of molecular weights of
PGA on the formation of DOX aggregates was
evaluated by mixing DOX and PGA or AS solutions
at room temperature, or by incubating the mixtures
at 60℃ for 10 min. As shown in Fig. 8A, the
higher the molecular weights of PGA, the higher
number of dense DOX-PGA aggregates were ob-
served, which were slightly different from DOX-AS
aggregates. 21) Incubating the DOX-PGA mixtures at
60℃ reduced the density of DOX-PGA aggregates,
while it contrarily increased size and produced
gelation-like precipitates in DOX-AS aggregates, as
observed in Fig. 8B.
In this study, AS-L produced the lowest
cytotoxicity among liposomal DOX groups, which
confirms that DOX was slowly released from a sta-
ble liposomal DOX. The lower pH of AS, which was
pH 5.2, enabled high DOX protonation, causing
small fraction of highly permeable DOX molecules
than DOX molecules entrapped in liposomes pre-
pared with higher pH of TEA solution (pH 6.5). It
has been reported that, besides DOX precipitation,
the interaction between DOX and sulfate anions
produces gelation, increasing the intrinsic stability
of DOX in AS-L, 10, 24, 25) as it has been confirmed in
Fig. 8B. However, it could not be observed in
PGA-Ls, as they showed a reduction in aggregate
densities after heating, concluding that DOX-PGA
aggregates have a different intrinsic stability from
DOX-AS mixtures in liposomes.
IV. In vivo antitumor activity of liposomal
DOX prepared with PGA after pretreat-
ment with ZOL
It has been reported that ZOL treatments en-
hance the antitumor efficacy of Doxil®. 16) ZOL could
modulate the tumor microenvironment by reducing
the number of TAMs, as well as reducing the pres-
ence of Kupffer cells in the liver that actively up-
take liposomes in the systemic circulation. In this
study, by using the same approach, ZOL was used
for tumor delivery of liposomal DOX prepared with
PGA in the presence of TEA buffer.
In order to evaluate the effect of modulating
the tumor microenvironment on the antitumor ac-
tivity of liposomal DOX, liposomal DOX was admin-
istered into LLC tumor-bearing mice that were pre-
treated with ZOL. The most stable PGA-liposome,
PGA20500-L, was chosen for evaluating the
antitumor efficacy of PGA-Ls. As shown in Fig. 9A,
compared with saline treatment groups that were
treated with and without ZOL pretreatment, a sin-
gle injection of PGA20500-L could inhibit tumor
growth up to day 14. Pre-treatment of tumor-
bearing mice with three injections of ZOL improved
the antitumor activity of PGA20500-L. During the
study, no remarkable reduction in body weight was
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Figure. 7In vitro cytotoxicities of liposomal DOX by ex-
posing DOX to murine LLC cells for 48 h. 21) DOX solu-
tion, AS-L, TEA-L, and PGA-Ls were added into the
cells at concentrations within the range of 0.005-2.5
g/mL. The cells were then incubated at 37℃ in a 5.0％
CO2 atmosphere incubator for 48 h, and the cell viabil-
ity was evaluated to determine IC50 values. Each value
represents the mean ± S.D. (n = 4).
Figure. 8Photomicrographs of DOX aggregate formation
by mixing DOX with PGA at molar ratio of DOX/L-
glutamic acid (the monomer unit of PGA) of 5.8, or with
0.25 M AS solution at room temperature (A), 21) or after
incubating the mixtures in a water bath at 60℃ for 10
min (B). The mixtures were allowed to stand at room
temperature for 30 min before the pictures were taken
under an optical microscope. Scale bar = 100 m.
observed (Fig. 9B).
In this study, administration of PGA20500-L in
combination with ZOL treatment could significantly
inhibit tumor growth in vivo compared with saline
treatment. It has been reported that ZOL produces
a decrease in TAM number and increases the num-
ber of open and wide vessels that are usually ob-
served in vascular normalization. 16) Based on the
results obtained, tumor blood flow may be restored,
thus reducing the high tumor interstitial fluid pres-
sure, and improving extravasation of liposomal
DOX into the tumor interstitium. The injection of
ZOL into LLC-tumor bearing mice before admini-
stration of liposomal DOX may modulate the tumor
microenvironment, providing benefits for tumor de-
livery and antitumor efficacy of liposomal DOX.
V. Summary
This study explored the use of PGA as a drug-
trapping agent to prepare liposomal DOX 21) , and
evaluated its antitumor efficacy in LLC tumor-
bearing mice in combination with ZOL injection.
The PGA with a high molecular weight increased
the stability of liposomal DOX, and administration
of this PGA-liposome into mice pre-injected with
ZOL solution could enhance the antitumor efficacy
of DOX.
PGA as an intraliposomal trapping agent af-
fected DOX release from liposomes as well as re-
ducing the in vitro cytotoxicity of DOX for LLC
cells. Increasing the molecular weight of PGA re-
duced DOX release from PGA-Ls. However, com-
pared to DOX-AS mixtures, DOX-PGA in the TEA
buffer system produced a different intrinsic stabil-
ity of DOX entrapped in liposomes. Exploiting ZOL
pretreatment for the administration of stable
liposomal DOX prepared with PGA increased the
antitumor activity of DOX. The high number of car-
boxyl groups in PGA could provide effective binding
sites for DOX, and thus might provide benefits as
a drug trapping agent for DOX in liposomes (PGA-
Ls). In addition, pre-treating mice with ZOL injec-
tion further improved the antitumor activity of
liposomal DOX in LLC tumor-bearing mice. Ad-
ministration of PGA-Ls after pre-treatment with
ZOL could potentially improve the antitumor effi-
cacy of DOX.
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Figure. 9 Percentage of tumor growth (A) and body
weights (B) of LLC tumor-bearing mice after admini-
stration of saline or PGA20500-L in combination with or
without ZOL pre-treatment. After tumor volume had
reached approximately 100-200 mm3, ZOL solution was
intravenously injected at a dose of 40 g ZOL per mice
for day 0, 1, and 2, followed by administration of
PGA20500-L at a dose of 5 mg DOX/kg mouse in day 3.
The untreated mice were injected with saline for three
consecutive days followed by saline injection. The effects
of ZOL treatments and administration of PGA-Ls on in-
hibition of tumor growth was expressed as a percentage
of tumor growth from day 0. Each value represents the
mean ± S.D. (n=4-5). Data were analyzed via one-way
ANOVA followed by Tukey’s HSD post-hoc test.
* P < 0.05 versus Saline+Saline treatment group.
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Doxorubicin (DOX) is an anthracycline compound that has been widely used for chemotherapy. However, it often
causes severe side effects to healthy tissues. To improve tumor delivery and antitumor efficacy of DOX, poly-α, L-
glutamic acid (PGA) has been proposed as an intraliposomal trapping agent for the preparation of stable liposomal DOX,
and its antitumor activity was further evaluated after modulating the tumor microenvironment with zoledronic acid
(ZOL) injection. PGA-liposomes (PGA-Ls) were prepared with triethylamine solution (pH 6.5) containing PGA as the hy-
drating buffer. Three different average molecular weights of PGA (4,800, 9,800, and 20,500) were used in this study. By
using phosphate-buffered saline (pH 7.4) as the extraliposomal buffer, DOX loading was highly achieved at 96% in PGA-
Ls. Increasing the incubation period and relative DOX amount to hydrogenated soya phosphatidylcholine (HSPC) during
drug loading decreased the entrapment efficiency of DOX in PGA-Ls. The optimal DOX loading was achieved by incubat-
ing liposome-DOX mixtures at 60°C for 10 min at a DOX/HSPC weight ratio of 1:5. Increasing the molecular weight
of PGA up to 20,500 resulted in stable DOX entrapment, thus reducing drug release from PGA-Ls. Corresponding to
drug release, the addition of PGA into liposomes reduced the cytotoxicity of DOX for Lewis lung carcinoma (LLC) cells.
Among PGA-Ls, PGA20500-L presented the most stable liposomal DOX. Further administration of PGA20500-L into LLC
tumor-bearing mice pre-treated with ZOL injection inhibited tumor growth up to day 14. These results suggest that PGA
could improve the stability of DOX encapsulation in PGA-Ls, and exploiting ZOL treatment for the administration of
PGA-Ls could be a potential method to improve antitumor efficacy of DOX.
